124 related articles for article (PubMed ID: 37910822)
1. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
Monk BJ; Colombo N; Tewari KS; Dubot C; Caceres MV; Hasegawa K; Shapira-Frommer R; Salman P; Yañez E; Gümüş M; Olivera Hurtado de Mendoza M; Samouëlian V; Castonguay V; Arkhipov A; Tekin C; Li K; Keefe SM; Lorusso D;
J Clin Oncol; 2023 Dec; 41(36):5505-5511. PubMed ID: 37910822
[No Abstract] [Full Text] [Related]
2. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
Monk BJ; Tewari KS; Dubot C; Caceres MV; Hasegawa K; Shapira-Frommer R; Salman P; Yañez E; Gümüş M; Hurtado de Mendoza MO; Samouëlian V; Castonguay V; Arkhipov A; Tekin C; Li K; Martin Nguyen A; Monberg MJ; Colombo N; Lorusso D
Lancet Oncol; 2023 Apr; 24(4):392-402. PubMed ID: 36878237
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial.
Tewari KS; Colombo N; Monk BJ; Dubot C; Cáceres MV; Hasegawa K; Shapira-Frommer R; Salman P; Yañez E; Gümüs M; Olivera Hurtado de Mendoza M; Samouëlian V; Castonguay V; Arkhipov A; Tekin C; Li K; Toker S; Keefe SM; Lorusso D
JAMA Oncol; 2024 Feb; 10(2):185-192. PubMed ID: 38095881
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826.
Nishio S; Yonemori K; Usami T; Minobe S; Yunokawa M; Iwata T; Okamoto A; Aoki Y; Itamochi H; Takekuma M; Harano K; Yamamoto K; Maruko T; Ugai H; Tekin C; Colombo N; Fujiwara K; Hasegawa K; Ushijima K
Cancer Sci; 2022 Nov; 113(11):3877-3887. PubMed ID: 35792064
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
[TBL] [Abstract][Full Text] [Related]
6. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.
de Castro G; Kudaba I; Wu YL; Lopes G; Kowalski DM; Turna HZ; Caglevic C; Zhang L; Karaszewska B; Laktionov KK; Srimuninnimit V; Bondarenko I; Kubota K; Mukherjee R; Lin J; Souza F; Mok TSK; Cho BC
J Clin Oncol; 2023 Apr; 41(11):1986-1991. PubMed ID: 36306479
[No Abstract] [Full Text] [Related]
7. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.
Novello S; Kowalski DM; Luft A; Gümüş M; Vicente D; Mazières J; Rodríguez-Cid J; Tafreshi A; Cheng Y; Lee KH; Golf A; Sugawara S; Robinson AG; Halmos B; Jensen E; Schwarzenberger P; Pietanza MC; Paz-Ares L
J Clin Oncol; 2023 Apr; 41(11):1999-2006. PubMed ID: 36735893
[No Abstract] [Full Text] [Related]
8. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
Garassino MC; Gadgeel S; Speranza G; Felip E; Esteban E; Dómine M; Hochmair MJ; Powell SF; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Kurata T; Gray JE; Schwarzenberger P; Jensen E; Pietanza MC; Rodríguez-Abreu D
J Clin Oncol; 2023 Apr; 41(11):1992-1998. PubMed ID: 36809080
[No Abstract] [Full Text] [Related]
9. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
Colombo N; Dubot C; Lorusso D; Caceres MV; Hasegawa K; Shapira-Frommer R; Tewari KS; Salman P; Hoyos Usta E; Yañez E; Gümüş M; Olivera Hurtado de Mendoza M; Samouëlian V; Castonguay V; Arkhipov A; Toker S; Li K; Keefe SM; Monk BJ;
N Engl J Med; 2021 Nov; 385(20):1856-1867. PubMed ID: 34534429
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha SY; Oh DY; Yañez P; Bai Y; Ryu MH; Lee J; Rivera F; Alves GV; Garrido M; Shiu KK; Fernández MG; Li J; Lowery MA; Çil T; Cruz FM; Qin S; Luo S; Pan H; Wainberg ZA; Yin L; Bordia S; Bhagia P; Wyrwicz LS;
Lancet Oncol; 2023 Nov; 24(11):1181-1195. PubMed ID: 37875143
[TBL] [Abstract][Full Text] [Related]
12. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Winer EP; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Zhou X; Karantza V; Mejia J; Cortes J;
Lancet Oncol; 2021 Apr; 22(4):499-511. PubMed ID: 33676601
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
[TBL] [Abstract][Full Text] [Related]
15. First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Satouchi M; Nosaki K; Takahashi T; Nakagawa K; Aoe K; Kurata T; Sekine A; Horiike A; Fukuhara T; Sugawara S; Umemura S; Saka H; Okamoto I; Yamamoto N; Sakai H; Kishi K; Katakami N; Horinouchi H; Hida T; Okamoto H; Atagi S; Ohira T; Han SR; Noguchi K; Ebiana V; Hotta K
Cancer Sci; 2020 Dec; 111(12):4480-4489. PubMed ID: 32926507
[TBL] [Abstract][Full Text] [Related]
16. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Vandormael K; Riccio A; Yang J; Pietanza MC; Brahmer JR
J Clin Oncol; 2019 Mar; 37(7):537-546. PubMed ID: 30620668
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.
Boyer M; Şendur MAN; Rodríguez-Abreu D; Park K; Lee DH; Çiçin I; Yumuk PF; Orlandi FJ; Leal TA; Molinier O; Soparattanapaisarn N; Langleben A; Califano R; Medgyasszay B; Hsia TC; Otterson GA; Xu L; Piperdi B; Samkari A; Reck M;
J Clin Oncol; 2021 Jul; 39(21):2327-2338. PubMed ID: 33513313
[TBL] [Abstract][Full Text] [Related]
18. First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.
Takahashi S; Oridate N; Tanaka K; Shimizu Y; Fujimoto Y; Matsumoto K; Yokota T; Yamazaki T; Takahashi M; Ueda T; Hanai N; Yamaguchi H; Hara H; Yoshizaki T; Yasumatsu R; Nakayama M; Shiga K; Fujii T; Mitsugi K; Takahashi K; Nohata N; Gumuscu B; Swaby RF; Tahara M
Int J Clin Oncol; 2022 Dec; 27(12):1805-1817. PubMed ID: 36264378
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK; Wu YL; Kudaba I; Kowalski DM; Cho BC; Turna HZ; Castro G; Srimuninnimit V; Laktionov KK; Bondarenko I; Kubota K; Lubiniecki GM; Zhang J; Kush D; Lopes G;
Lancet; 2019 May; 393(10183):1819-1830. PubMed ID: 30955977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
